CP and COVID-19: Despite the above, preliminary results regarding CP transfusions in COVID-19 patients have indicated the apparent absence of antibody-related adverse effects, which could be explained by the preferential binding of the NAbs to the virus, rather than to immune cells or tissues that would be needed to enhance the proinflammatory immune responses responsible for adverse effects (e.g., ADE) [39].